Alector, Inc. — 2019 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019. This is an annual filing, not a standalone fourth-quarter report; selected Q4 figures are included below. Alector is a clinical-stage biopharmaceutical company developing immuno-neurology therapies for neurodegenerative diseases. It had no approved products or product-sales revenue.
Financial performance and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $21.2 million | $27.7 million |
| Research and development expense | $100.5 million | $73.0 million |
| General and administrative expense | $35.1 million | $11.9 million |
| Operating loss | $114.4 million | $57.3 million |
| Net loss | $105.4 million | $52.2 million |
| Net loss per share, basic and diluted | $1.71 | $4.62 |
| Cash, cash equivalents and marketable securities at year-end | $353.1 million | $290.4 million |
| Working capital at year-end | $295.5 million | $245.2 million |
| Operating cash flow | $(99.3) million | $127.5 million |
Revenue was primarily collaboration revenue from AbbVie; Alector reported no product sales. The company had a $219.8 million accumulated deficit. No financial borrowings are identified in the supplied filing text; operating lease liabilities were $48.0 million at year-end, with $71.7 million of undiscounted lease payments. Gross margin is not a meaningful disclosed measure for this development-stage business.
Q4 2019: Revenue was $6.0 million, operating loss was $32.3 million, net loss was $30.5 million, and net loss per share was $0.45. Q4 2018 revenue was $9.1 million and net loss was $17.4 million.
Material changes versus prior periods
- Annual revenue fell $6.5 million, principally because higher forecast development costs for the AbbVie programs reduced collaboration revenue recognized under the cost-based recognition method.
- R&D expense increased $27.5 million as clinical and pipeline activity, staffing, and facilities costs grew. G&A expense rose $23.2 million, including higher staffing, public-company, facilities, and legal costs.
- Net loss approximately doubled, and operating cash flow shifted from a $127.5 million inflow in 2018 to a $99.3 million outflow in 2019. The prior-year inflow included AbbVie’s $200 million upfront payment received in January 2018; 2019 cash use reflected operating losses and recognition of deferred collaboration revenue.
- The 2019 IPO generated $168.2 million in net proceeds. After year-end, a January 2020 follow-on offering generated approximately $224.5 million net proceeds. The company said year-end liquidity, based on its operating plan, would fund operations for at least 12 months from the filing date.
Pipeline, outlook and principal risks
- AL001: In Phase 2 for FTD, including FTD-GRN and an additional FTD-C9orf72 genetic subgroup. Phase 1b results showed restoration of PGRN levels; exploratory biomarker findings included normalization of certain CSF proteins and a preliminary NfL reduction in a small sample. Management expected preliminary Phase 2 data during 2020 and planned to advance toward Phase 3 in FTD-GRN, subject to regulatory consultation.
- AL002: Phase 1a in healthy volunteers showed dose-dependent target engagement and a CSF biomarker response. Phase 1b in Alzheimer’s patients was underway, with data expected in 2020. A nonhuman-primate toxicology study found inflammation in parts of the eye; additional ophthalmological monitoring was added to the clinical trial.
- AL003: Phase 1a target engagement was reported, but two volunteers experienced treatment-related serious adverse events—aseptic hip monoarthritis and a reaction involving rash, fever and thrombocytopenia. Both recovered after corticosteroid treatment. Screening for a Phase 1b Alzheimer’s study began in late 2019, with dosing commencing in January 2020.
- AL101: A Phase 1 study in healthy volunteers began in Q4 2019; Phase 1a data were expected in 2020.
- AbbVie holds options over the AL002 and AL003 programs. Alector had received $205.0 million in upfront payments and could be eligible for up to $985.6 million in additional option and milestone payments, plus potential profit sharing or royalties. Future milestone consideration was not included in the reported transaction price because it remained contingent.
- Management expected increased R&D spending and continued losses. Development, clinical-trial enrollment and results, regulatory review, third-party manufacturing, collaboration decisions, reimbursement, competition, and additional financing are significant uncertainties. The filing also described possible COVID-19-related disruptions to trials and operations, and uncertainty around public-market access.
- Alector initiated confidential arbitration against former consulting co-founder Asa Abeliovich over alleged contract breaches and misuse of confidential information; the company could not assess the outcome. The company reported no other litigation it considered likely to have a material adverse effect.
Most important facts for investors to verify
- Whether AL001 Phase 2 data support clinical benefit—not just biomarker changes—and whether the planned Phase 3 path remains feasible.
- Updated safety findings and monitoring for AL002 and AL003, including the eye findings for AL002 and the serious adverse events in the AL003 study.
- Cash burn, collaboration-revenue estimates and runway against current trial plans; the stated runway is based on management assumptions, and the 2020 follow-on offering occurred after year-end.
- AbbVie’s option decisions, future milestone eligibility, cost-sharing obligations, and the economics of any profit-share or royalty election.
- Potential effects of the arbitration, lease commitments, clinical-trial execution, and COVID-19 disruptions on spending and timelines.